Ask any hospital administrator which company owns robotic surgery, and you’ll get the same answer every time: Intuitive Surgical (NASDAQ: ISRG). Since earning its first FDA clearance in 1999, Intuitive has held more than 90% of the robotic-assisted soft tissue surgery market for over two decades. In 2025, it crossed $10 billion in annual revenue for the first time — making it not just a medtech leader, but one of the most durable business models in all of healthcare.
This piece covers everything an informed investor or industry observer needs to know: the product lineup, the business model, the financials, the competitive landscape, and the risks worth taking seriously.
1. Company Overview — Origins and Where It Stands Today
- 1995 — Founded in Sunnyvale, California. The founding team built on remote surgery technology originally developed at SRI International for the U.S. military.
- 1999 — First FDA clearance for the da Vinci Surgical System — laparoscopic surgical assistance.
- 2000 — Listed on Nasdaq (ISRG) at roughly $9 per share.
- 2006–2014 — da Vinci S → Si → Xi platform upgrades. Rapid expansion into prostatectomy, hysterectomy, and cholecystectomy procedures.
- March 2024 — da Vinci 5 launched: 10,000x computing power increase, force feedback, expanded digital platform.
- 2025 — Full-year revenue hits $10.06B. Ranks #459 on the Fortune 500, #43 in healthcare.
CEO Gary Guthart has been at the helm since 2010. An engineer by training, his deep technical background helps explain the company’s consistent long-term R&D focus — a relative rarity in big-cap medtech.
2. Product Portfolio — da Vinci and Ion
The da Vinci Platform: Generation by Generation
| Model | Launch | Configuration | Key Features | Status |
|---|---|---|---|---|
| da Vinci Xi | 2014 | 4-port multiport | Multi-quadrant reach, overhead boom arm | Active (legacy) |
| da Vinci X | 2017 | 4-port multiport | Lower-cost Xi variant for smaller facilities | Active (legacy) |
| da Vinci SP | 2018 | Single-port | Multiple instruments through one incision | Active |
| da Vinci 5 | Mar 2024 | 4-port multiport | 10,000x compute, force feedback, AI-integrated | Current flagship |
The da Vinci 5 is a meaningful generational leap, not just an incremental refresh. The 10,000x jump in computing power enables real-time data capture and AI-assisted analytics, and it introduces the first true force feedback in the da Vinci line. In 2025, 870 of the 1,721 da Vinci systems placed were da Vinci 5 units — over half of all new placements have already converted to the latest generation.
📌 da Vinci 5 — Regulatory Clearance Tracker
– U.S. FDA: Initial clearance March 2024 → Broad commercial rollout by H1 2025
– EU (MDR): Certified July 2025 for adult and pediatric laparoscopic and thoracoscopic procedures
– Japan (PMDA): Cleared June 2025 across all indications approved for the da Vinci Xi
Ion — Expanding Beyond the OR
Ion is a robotic endoluminal platform for minimally invasive lung biopsies. Unlike da Vinci, it operates in diagnostics rather than surgery — guiding a catheter through the bronchial tree to sample pulmonary nodules. Ion procedure volume grew 51% in 2025, and the installed base reached 995 systems by year-end. The market is still early-stage, which is exactly where the growth opportunity lies.
3. Business Model — A Textbook Razor-and-Blade
Once you understand Intuitive’s revenue structure, the durability of the business becomes obvious. It’s one of the cleanest examples of a recurring-revenue flywheel in all of large-cap equities.
FY2025 Revenue Mix (Estimated)
| Segment | Share | Description |
|---|---|---|
| Instruments & Accessories | ~61% | Required consumables per procedure. The core recurring revenue engine. |
| Systems | ~17% | da Vinci hardware sales and operating leases. Usage-based arrangements growing. |
| Services | ~22% | Installation, training, 24/7 technical support, preventive maintenance. |
The Razor: A da Vinci system runs roughly $1.5M–$2.5M. Usage-based and operating lease models are capturing a growing share of new placements.
The Blade: Proprietary instruments must be replaced after a set number of uses. Every procedure drives recurring revenue — automatically.
In total, 85% of revenue is recurring. Once a hospital installs a da Vinci system, it commits to buying Intuitive’s instruments for every procedure it runs. That lock-in is precisely why Morningstar assigns ISRG a Wide Moat rating.
💡 The Installed Base Compounding Effect
With 11,106 systems installed globally as of end-2025, each one generating annual consumable revenue, the business has a large and growing base of recurring cash flows that compounds independently of new system sales. This structural leverage is why EPS growth consistently outpaces top-line revenue growth.
4. Financial Performance — The Numbers Behind the Story
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $7.12B | $8.35B | $10.06B | +20.5% |
| Net Income | $1.80B | $2.33B | $2.86B | +23% |
| da Vinci System Placements | 1,370 | 1,526 | 1,721 | +13% |
| — of which da Vinci 5 | — | 362 (24%) | 870 (51%) | Next-gen conversion accelerating |
| Installed Base | 8,616 | 9,902 | 11,106 | +12% |
| da Vinci Procedure Growth | +22% | +17% | +18% | Consistent trajectory |
Historical revenue reference:
– 2021: $5.71B
– 2022: $6.22B (+9%)
– 2023: $7.12B (+14%)
– 2024: $8.35B (+17%)
– 2025: $10.06B (+20.5%)
The 2026 outlook holds up. Management guided for da Vinci procedure growth of +13–15% for the full year. One watch item: tariff exposure has pushed gross margin guidance down to 65–66.5%, from 69.1% in 2024.
5. Competitive Landscape — The First Real Challengers in 25 Years
2025 marked the year Intuitive’s moat faced its first genuine tests. That doesn’t mean the moat has cracked — but the market is no longer a one-horse race.
| Competitor | System | Target Procedures | Status (Apr 2026) | Threat Level |
|---|---|---|---|---|
| Medtronic | Hugo RAS | Urology, laparoscopy | FDA urology clearance Dec 2025; U.S. commercial launch targeted FY2026 | Moderate — price competitive |
| J&J MedTech | Ottava | General soft tissue | FDA De Novo submitted Jan 2026; U.S. IDE trials ongoing | Moderate — pre-commercial |
| CMR Surgical | Versius | Cholecystectomy, laparoscopy | FDA clearance Oct 2024; 30+ countries, 30,000+ procedures | Low — scale gap is significant |
| Stryker | Mako | Orthopedics | Orthopedic robotics leader; does not compete in soft tissue | Low — different market |
⚠️ China Risk — A Growing Headwind
Provincial tender policies in China are increasingly favoring domestic robotic surgery suppliers. Intuitive faces a gradual squeeze in one of its key growth markets, with longer-term revenue at risk if local competitors gain clinical traction.
The prevailing analyst view is measured: Medtronic and J&J will eventually show up as real competitors, but meaningful market share erosion in the near term is unlikely. A new entrant doesn’t just need better hardware — it needs to replicate the entire installed base, training network, and procedure data ecosystem Intuitive has built over 25 years.
6. Growth Drivers and Risks — Both Sides of the Ledger
Bull Case
- da Vinci 5 upgrade cycle: Thousands of legacy Xi and X systems in the field represent a multi-year hardware refresh opportunity
- International expansion: OUS procedure volume grew +23% in 2025, now ~35% of global total. Europe, India, and the Middle East have significant runway
- Ion platform growth: Lung cancer screening demand rising. Ion procedures +51% in 2025; installed base approaching 1,000 units
- Installed base compounding: 11,106 systems × annual consumable revenue creates a self-reinforcing revenue floor
- AI and digital integration: da Vinci 5’s data platform is evolving into a hospital workflow optimization tool — expanding Intuitive’s value beyond hardware
Bear Case
- Valuation: ~57x earnings. A lot of good news is priced in. Any guidance miss could trigger a sharp selloff
- Tariff exposure: Gross margin guidance compressed to 65–66.5% for 2025, down from 69.1% in 2024
- China headwinds: Local-preference procurement policies represent a structural drag on a key international market
- Cybersecurity: A phishing attack in early 2026 breached certain internal IT systems. Surgical systems were unaffected, but the incident flagged an enterprise security gap
- Competitive pressure: Medtronic’s Hugo U.S. launch and J&J’s Ottava FDA submission signal a structurally more competitive landscape ahead
7. Investment Perspective — What Kind of Stock Is ISRG?
ISRG doesn’t fit neatly into growth stock or value stock buckets. The better label is compounding monopoly. It spent two decades locking in a dominant market position and is now growing revenue at 20%-plus from a $10 billion base. Morningstar rates it Wide Moat. Among the 16 analysts covering the name, the consensus is Buy, with a 12-month price target of $606 (as of April 2026).
Volatility is part of the deal. ISRG rallied nearly 40% from its October 2025 low of ~$425 to a late-2025 peak near $590, before pulling back to the $460 range by April 2026. For a high-multiple growth name, that sensitivity to earnings catalysts is expected.
✅ Key Metrics to Watch Each Quarter
Three numbers tell you most of what you need to know: ① da Vinci 5 new system placements ② worldwide procedure volume growth ③ instruments and accessories revenue trajectory. When all three are healthy simultaneously, the rest of the income statement tends to take care of itself.
Robotic surgery is becoming the standard of care faster than most observers expected. More than 3.1 million patients were treated with da Vinci systems in 2025 alone, and cumulative procedures have surpassed 20 million since inception. A company that spent 25 years building this position is now deploying its most capable platform to date — while the first credible competitors are still working through regulatory pipelines. In any market, the most interesting moment is when a monopoly starts to be tested. That moment is now.
📎 References: Intuitive Surgical IR · SEC 8-K Filings · MedTech Dive
⚠️ This article is for informational purposes only and does not constitute investment advice.